The role of capecitabine in the management of tumors of the digestive system

Reviews on Recent Clinical Trials

Volumn 4, Issue 1, 2009, Pages 1-11

  Gennatas, Constantine ^a,c   Michalaki, Vasiliki ^a   Gennatas, Spyridon ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c NONE   (Greece)

Author keywords

Biliary tract cancer; Capecitabine; Colorectal cancer; Esophageal cancer; Gallbladder cancer; Gastric cancer; Gastroesophageal cancer; Hepatic cancer; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX; TAXOID; VASCULOTROPIN A;

ABDOMINAL PAIN; ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GALLBLADDER CANCER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING; WOUND HEALING IMPAIRMENT; ADJUVANT CHEMOTHERAPY; BILE DUCT TUMOR; COLON TUMOR; DIGESTIVE SYSTEM TUMOR; DRUG ANTAGONISM; ESOPHAGUS TUMOR; GALLBLADDER TUMOR; HEPATIC DUCT; LIVER TUMOR; METASTASIS; PANCREAS TUMOR; PATHOLOGY; RECTUM TUMOR; STOMACH TUMOR; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; COLONIC NEOPLASMS; DEOXYCYTIDINE; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RECTAL NEOPLASMS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62449141070     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709787047576     Document Type: Review

References (82)

1. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006; 107: 221-31.
2. Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005; 27: 23-44.
3. McKendrick J, Coutsouvelis J. Capecitabine: Effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005; 6: 1231-9.
4. National Cancer Institute. PDQ® Cancer Information Summaries: Treatment. [Online]. [cited 2007 Aug 01]; Available from: URL: http://www.cancer.gov/cancertopics/pdq/treatment
5. Ku GY, Ilson DH. Esophageal cancer adjuvant therapy. Cancer J 2007; 13: 162-7.
6. Czito BG, Kelsey CR, Hurwitz HI, et al. A phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007; 15: 1002-7.
7. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-Ray irradiation induces thymidine phosphorylase and enhanhes the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-53.
8. Cunningham DR, Starling S, Iveson N, et al. NCRI Upper GI Study Group. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial abstract. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (Suppl 18): LBA4017.
9. Kang YK, Shin WK, Chen DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results abstract. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (Suppl 18): LBA4018.
10. Lorenzen S, Duyster J, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second -line metastatic oesophageal caner: Final results of a phase II trial. Br J Cancer 2005; 92: 2129-33.
11. ClinicalTrials.gov. [Online]. [cited 2007 Aug 01]; Available from URL: http://www.clinicaltrials.gov/ct/show
12. Hong YS, Song SY, Lee SI, et al. A Phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15: 1344-7.
13. Kim JG, Sohn SK, Kim DH. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-5.
14. Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188-94.
15. Park YH, Ryoo BY, Choi SJ, Kim HT. A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329-33.
16. Damstrup L, Wadervang K, Hansen HH. Carboplatin, capecitabine and docetaxel (CaCD) in patients with advanced gastric or gastroesophageal (GE) adenocarcinoma. A single institutional experience (Abstract 895P). Ann Oncol 2004; 15(Suppl 3): iii235.
17. Burge ME, Smith D, Topham C, et al. A phase I and II study of 2-weekly irinotecan with capecitabine in adnacedgastroesophageal adenocarcinoma. Br J Cancer 2006; 8: 1281-6.
18. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1407-11.
19. Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A Phase II study from the North Central Cancer Treatment Group. Ann Oncol 2005; 17: 29-34.
20. Park YH, Kim B-S, Ryoo B-Y, Yang SH. Oxaliplatin and capecitabine combination chemotherapy for patients with advanced gastric carcinoma: A pilot study results [abstract 57]. Presented at the Second Annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Miami, Florida; 2005.
21. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92(11): 1976-83.
22. Viteri A, Barcelo-Galindez R, Rubio I, et al. Cisplatin and capecitabine as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (Meeting Abstracts) 2004; 22: 418.
23. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
24. Kim JG, Sohn SK Kim DH. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-5.
25. Monga DK, O'Connell MJ. Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 2006; 13: 1021-34.
26. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to IV 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-43.
27. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-704.
28. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois.
29. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 25: 2198-220.
30. National Comprehensive Cancer Network. Colon cancer.v.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed October 18, 2007.
31. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
32. Makatsoris T, Kalofonos HP, Aravantinos G, et al. A phase II study of capecitabine plus oxaliplatin (XELOX): A new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer 2005; 35: 103-9.
33. Hochster HS, Hart LL, Ramanathan RK. Safety and efficacy of oxaliplatin/ fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Stusy. J Clin Oncol 2006 ASCO Annual Meeting proceedings Part I. (June 20 Suppl), vol. 24(185): 2006; 3510.
34. US Food and Drug Administration. Irinotecan hydrochloride injection, 20 mg/nL: medical rationale. Available at: http://www.fda.gov/ohrms/dockets/ dockets/05p0496/05p-0496-cp00001-02-Attachment-01-vol1.pdf. Accessed October 18, 2007.
35. Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-87.
36. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22: 1022.
37. Michalaki V, Gennatas C, Gennatas S, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. J Clin Oncol (Meeting Abstracts) 2007; 25: 14602.
38. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy data. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting: Chicago, Illinois. Abstract 4027; 2007.
39. Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Program and abstracts of the 42nd Annual Meeting of the American Society of Clinical Oncology: Atlanta, Georgia. Abstract 3506; 2006.
40. Capdevila J, Mendez G, Macarulla T, Ramos FJ, Casado E, Tabernero J. New approaches in systemic treatment of advanced colorectal cancer: The molecular targets era. Expert Rev Anticancer Ther 2007; 7: 1027-1041.
41. Adams R, Maughan T. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 2007; 7: 503-18.
42. Sorscher SM. Biological therapy update in colorectal cancer. Expert Opin Biol Ther 2007; 7: 509
43. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/ NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Program and abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Orlando, Florida. Abstract 238; 2007.
44. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting: Chicago, Illinois. Abstract 4028; 2007.
45. Schmiegel W, Reinacher-Schick A, Freier W, et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting: Chicago, Illinois. Abstract 4034; 2007.
46. Ramanathan RK, Rajasenan K, Crandall T, Balaban EP, et al. Phase II study of the A-ICOX regimen bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox) for untreated advanced colorectal cancer (CRC). Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 2-4, 2007; Chicago, Illinois.
47. Cartwright TH, Kuefler P, Cohn A, et al. Results of a phase II trial of cetuximab + XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 2-4, 2007; Chicago, Illinois.
48. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 2007; 370: 105-7.
49. Rothenberg ML, Navarro M, Butts C, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 2-4, 2007; Chicago, Illinois.
50. Gennatas CG, Michalaki V, Gennatas S, Kouvaris J, Smyrniotis V, Vasiliou J. Mitomycin -C and capecitabine as salvage chemotherapy in pre-treated patients with advanced colorectal cancer. J Clin Oncol (Meeting Abstracts) 2007; 25: 14595.
51. Chong G, Dickson JL, Cunningham D, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005 5; 93(5): 14595.
52. Koopman M, Antoninin NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomized controlled trial. Lancet 2007 14; 370(9582): 135-42.
53. Watkins DJ, Jackson C, Chua Y, et al. A prospective study of oxaliplatin and capecitabine (CapeOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 2-4, 2007; Chicago, Illinois.
54. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006; 17: 361-71.
55. Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious. Br J Cancer 2006; 94: 363-71.
56. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
57. Roedel C, Arnold D, Hipp M, Liersch T, Sauer R. Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer. Program and abstracts of the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 26-28, 2007; San Francisco, California.
58. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
59. Patt YZ, Hassan M, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101(3): 578-86.
60. Tai CJ, Chiou HY, Wu CH, Pan S, Liu JD. Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high dose fluorouracil plus leucovorin. Onkologie 2006; 29(4): 179-80.
61. Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6: 3.
62. O'Neil BH, Bernard SA, Goldberg RM, et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida.
63. Blechacz B, Heimbach JK, Haddock MG, et al. Liver transplantation with neoadjuvant chemoradiation for unresectable hilar cholangiocarcinoma. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida.
64. Shinohara ET, Mitra N, Guo M, Sun W, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of cholangiocarcinomas. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida.
65. Saif MW. Pancreatic cancer: Are we moving forward yet? High-light from the Gastrointestinal Cancers Symposium. Orlando, Fl, USA. January 20th, 2007. JOP 2007; 8(4): 365-73.
66. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-7.
67. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-40.
68. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Program and abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 17-21, 2007; Orlando, Florida.
69. Iyer RV, Yu J, Garrett CR, et al. Gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (APC): final results of the multicenter phase II study. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida.
70. Chua Yj, Cunningham D. Chemotherapy for advanced pancreatic cancer. Best pract Res Clin Gastroenterol 2006; 20(2): 327-48.
71. Fine RL, Fogelman DR, Sherman W, et al. The GTX regimen: a biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 2003; 22: 1129.
72. Allendorf JD, Lauerman M, Bill A, et al. Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival. J Gastrointest Surg 2008; 12(1): 91-100.
73. Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from Smith DB, Neoptolemos JP. Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 2006; 7: 1633-9.
74. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: A review of recent advances. Expert Opin Investig Drugs. 2006; 15: 1395-410.
75. The '43rd ASCO Annual Meeting'. Chicago, Il, USA. June 1-5, 2007.
76. Kindler HL. Pancreatic cancer: An update. Curr Oncol Rep 2007; 9(3): 170-6.
77. Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol 2007; 34 (2 Suppl 1): S25-30.
78. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 292-7.
79. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III randomized trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
80. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
81. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
82. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant therapy for stage III colon cancer. N Engl J Med 2005; 352: 2696-704.